Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers

Ali Jabbari, Nhan Nguyen, Jane E Cerise, Grace Ulerio, Annemieke de Jong, Raphael Clynes, Angela M Christiano, Julian Mackay-Wiggan, Ali Jabbari, Nhan Nguyen, Jane E Cerise, Grace Ulerio, Annemieke de Jong, Raphael Clynes, Angela M Christiano, Julian Mackay-Wiggan

No abstract available

Keywords: JAK inhibitors; alopecia areata; biomarkers; tofacitinib.

Conflict of interest statement

Conflicts of Interest:

The authors have declared no conflicting interests.

Figures

Figure 1

Clinical photographs of and serum CXCL10 and ALADIN profile of skin biopsy samples from an AA patient treated with tofacitinib. Top panel, Photographs were taken of the posterior scalp over 16 weeks of treatment with tofacitinib 5 mg twice daily. Bottom left panel, Blood and skin samples were taken at baseline and after 4 weeks of treatment with tofacitinib. CXCL10 ELISA was performed. Bottom middle panel, Heat map of ALADIN genes from skin samples taken from healthy control patients (normal) and the AA patient at baseline (T0) and after 4 weeks of treatment (T4). Bottom right panel, ALADIN plot of skin samples taken from healthy control patients (black) and the AA patient at baseline (red) and after 4 weeks of treatment (yellow).